Novartis India credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY25Mar 2025FY24Mar 2024FY23Mar 2023
0.01.4—
−52.1−595—
−0.07×−0.80×—
0.00×0.02×—
−0.57×−9.11×—
115.88×42.05×33.73×
0.0%0.2%—
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

NOVARTIND₹1,812.80

Novartis India Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLPARNAXLABSGRLSHUKRAPHARSUNLOC
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
Total Debt—1.40.0
Net Debt—-594.7-52.1
Net Debt/Equity—-0.80-0.07
Total Debt/EBITDA—0.020.00
Net Debt/EBITDA—-9.11-0.57
Interest Coverage (EBIT/Interest)33.7342.05115.88
Total Debt/Total Capital %—0.190.00
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.